Living with Lynch syndrome, nature’s quiet resilience teaches me to accept change, find calm, and stay rooted through life’s ...

Tagrisso with chemo significantly improved survival and progression-free outcomes versus Tagrisso alone in newly diagnosed ...

Data from the KEYNOTE-B61 trial show tumor shrinkage in different types of kidney cancer, including papillary and chromophobe ...

Disparities in cancer care can often lead to delays, disruptions, and barriers to timely treatment, leading to an unmet need ...

Q-TWiST may help patients with advanced kidney cancer and their doctors weigh treatment options by focusing on quality of ...

Keeping my part-time teaching job during breast cancer treatment gave me purpose, connection and strength — and it helped me ...

IV infiltration and extravasation remind this cancer patient of the constant challenges of speaking up and advocating for ...

Treatment with Zusduri had a median duration of response of 3.5 years and event-free survival of two years in low-grade ...

Researchers are building on the success of CAR T therapy in blood cancers to explore its use in clear cell renal cell ...

The FDA's Oncologic Drugs Advisory Committee has casted their votes on the utilization of certain treatments in the multiple ...

Patients with skin cancer who were fed a high-fiber diet showed better response rates to treatment and longer event-free ...

After attending several cancer support groups, I reflect on what makes them helpful, inclusive and healing — and invite ...